QRISK3评分可预测骨髓增殖性肿瘤患者的血栓风险
该研究分析937例骨髓增殖性肿瘤患者(490例原发性血小板增多症、447例真性红细胞增多症),中位随访85和95个月,分别报告52和73例血栓栓塞事件。QRISK3评分>7.5%可进一步分层高危血栓风险,在QRISK3≥7.5%患者中接受降细胞治疗较主动监测降低血栓风险。
要点
- QRISK3评分>7.5%在低危和高危患者中均优于标准风险评估。
- QRISK3≥7.5%的ET患者中,降细胞治疗组79.7%无血栓,未治疗组64.1%(p=0.018)。
- QRISK3≥7.5%的PV患者中,降细胞治疗组86.9%无血栓,未治疗组57.1%(p=0.034)。
核心结论
- QRISK3评分可识别可能适合降细胞治疗的患者,并提供评估、监测和降低心血管风险的工具。
研究设计与样本
- 分析937例骨髓增殖性肿瘤患者数据,其中490例原发性血小板增多症和447例真性红细胞增多症。
- 中位随访分别为85个月和95个月。
主要发现
- 原发性血小板增多症队列报告52例血栓栓塞事件,真性红细胞增多症队列报告73例。
- 诊断时中位QRISK3评分在常规高危患者中更高:原发性血小板增多症高危4.2 vs 低危2.4,真性红细胞增多症高危8.8 vs 低危2.8,p<0.001。
- QRISK3评分>7.5%在低危和高危患者中均表现出优于标准风险评估的血栓风险分层潜力。
- QRISK3≥7.5%的原发性血小板增多症患者中,降细胞治疗组79.7%无血栓 vs 未降细胞治疗组64.1%(p=0.018)。
- QRISK3≥7.5%的真性红细胞增多症患者中,降细胞治疗组86.9%无血栓 vs 未降细胞治疗组57.1%(p=0.034)。
关键数值与推荐
- QRISK3评分>7.5%被认定为识别高危患者的阈值。
- QRISK3≥7.5%患者中,使用降细胞治疗而非主动监测与血栓风险降低相关。
临床怎么用
- QRISK3评分可识别可能适合降细胞治疗的患者。
- QRISK3评分提供评估、监测和降低心血管风险的工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromboembolic events (TE) represent the commonest cause of morbidity and mortality in polycythemia vera (PV) and essential thrombocythaemia (ET). The QRISK3 model is a tool for predicting TE in the general population, with 7.5% recognised as a threshold to identify high-risk patients. We analyzed data of 937 patients (490 ET and 447 PV) with a median follow-up of 85 and 95 months, reporting an occurrence of 52 and 73 TE, respectively. Median QRISK3 scores at diagnosis were higher in conventional high-risk patients in both cohorts (ET; 4.2 in high-risk vs. 2.4 in low-risk, PV; 8.8 vs. 2.8, p < 0.001). During follow-up, a QRISK3 score greater than 7.5%, demonstrated potential to further stratify individuals at high risk of TE, outperforming standard risk assessments in both low and high-risk patients. Using cytoreductive treatment instead of active surveillance in patients with QRISK3 ≥ 7.5% conferred a reduced risk of thrombosis in both cohorts. Of this group, 79.7% with ET and 86.9% with PV, on cytoreductive therapy, remained thrombosis free, compared with 64.1% and 57.1% of those not receiving cytoreductive therapy (p = 0.018/0.034). QRISK3 identifies patients in whom cytoreductive therapies may be indicated, and provides a tool that allows patients to assess, monitor and reduce their cardiovascular risk.
引用
- Duminuco A, Vaghela R, Virdee S, et al. QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms. Leukemia. 2025. PMID: 40707675. doi:10.1038/s41375-025-02681-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。